Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer – Clinical and Translational Advances

This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr. Louie presents insights from recent pivotal trials such as PACIFIC, PACIFIC-2, and Checkmate 73L, focusing on integrating immunotherapy with radiotherapy and optimizing sequencing, dose, and timing, while also addressing treatment-related toxicities, patient selection criteria, and the controversies surrounding the optimal sequencing of these therapies. Dr. Iyengar explores the NRG LU002 trial and other recent studies in the oligometastatic and oligoprogressive spaces, offering insights into how sequencing, dose, and timing impact the effectiveness of radiotherapy and immunotherapy combinations, as well as addressing ongoing debates in this area. Dr. Owen examines the potential of combining radiotherapy and immunotherapy in early-stage NSCLC, including findings from the recent Keynote-867 trial, while considering neoadjuvant approaches and the controversies regarding their clinical applicability. Dr. Schneiders dives into the biological mechanisms behind combination immunotherapy, focusing on immune modulation, biomarker development, and advanced genomic and proteomic techniques, along with exploring the controversies in biomarker discovery and their role in personalized medicine. Finally, an interactive Q&A session, moderated by Drs. Kim and Bahig, engages attendees and listeners in discussions about these advancements, the impact of sequencing and dosing, and the unresolved controversies shaping the future of radio-immunotherapy for lung cancer.

Topics:

  1. Continuing to Refine Radical Local Therapy Utilization in Advanced NSCLC – Immunotherapy Integration
    Puneeth Iyengar, MD, PhD
  2. Evidence for Efficacy and Sequencing Optimisation of Immunotherapy and Radiotherapy in Locally Advanced NSCLC Lung Cancer
    Alexander V. Louie, MD, PhD, MSc, FRCPC
  3. Combining RT and Immunotherapy in Early-Stage (Stage I-II) NSCLC - Is There a Future?
    Dawn Owen, MD, PhD
  4. Q and A - Part 1
    Jongmyung Kim, MD, PhD - Moderator
    Full Panel
  5. Translational Approaches to Optimize Radiotherapy-Immunotherapy Integration in NSCLC
    Famke L. Schneiders, MD, PhD
  6. Q and A - Part 2
    Jongmyung Kim, MD, PhD - Moderator
    Full Panel

This activity is available from December 23, 2025, through 11:59 p.m. Eastern time on December 22, 2027. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, pathologists, radiation biologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the impact of recent clinical trial data on the integration of immunotherapy and radiotherapy in NSCLC treatment strategies.
  • Discuss the latest clinical evidence supporting the use of combination immunotherapy, highlighting its efficacy, timing and sequencing with radiotherapy in various stages of NSCLC.
  • Analyze emerging biomarkers and basic science mechanisms driving the efficacy of combination therapies, and their implications for personalized treatment approaches in NSCLC.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/23/2025
Course expires: 
12/22/2027
Cost:
$149.00
Rating: 
0
  • Houda Bahig, MD, PhD, is employed by Centre Hospitalier de l’Universite de Montreal (CHUM). Dr. Bahig receives grant/research funding from AstraZeneca and Varian Medical Systems. 
  • Jongmyung Kim, MD, PhD, is employed by H. Lee Moffitt Cancer Center and Research Institute. 
  • Puneeth Iyengar, MD, PhD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Iyengar receives grant/research funding and salary support from Incyte. 
  • Alexander V. Louie, MD, PhD, MSc, FRCPC, is employed by Sunnybrook Health Sciences Centre, University of Toronto. Dr. Louie receives honoraria from AstraZeneca.
  • Dawn Owen, MD, PhD, is employed by Mayo Clinic. Dr. Owen receives grant/research funding and honoraria from AstraZeneca, UpToDate and Varian.
  • Famke L. Schneiders, MD, PhD, is employed by Cancer Center Amsterdam. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until December 22, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.